Worth reading
25Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
3 items taken from the company’s own explanation
What the company explained in this material
New initiatives
- Preparation for Telomelysin's manufacturing and marketing approval, NHI drug price listing, and launch
- Additional-indication trials outside esophageal cancer
- Overseas expansion prioritizing Asia and the United Kingdom, and sales partnerships
- Establishment of an in-house sales organization in Japan
- Bridging working capital from manufacturing through cash collection using bank borrowings
- Significant expansion of the workforce with drug discovery development experience and biomanufacturing skills
- Preparation to launch an investigator-initiated clinical trial of OBP-702 for pancreatic cancer
Key KPIsA metric the company considers important as a management benchmark.
- Local complete response rate50 %
- Local response rate63.9 %
- Number of complete response cases in the U.S. esophageal cancer CRT trial13/13
- 1-year survival rate in the U.S. esophageal cancer CRT trial60 %
- Cases without local recurrence12/13
- Number of patients starting treatment in the U.S. Phase 2 gastric cancer trial12/13
Market Size / Share
- Asia's share of global esophageal cancer patients70 %
- Number of esophageal cancer patients in Asia, including Japan39 10,000 people
- Number of esophageal cancer patients in China20 10,000 people
- Number of esophageal cancer patients in the EU and the United Kingdom5.4 10,000 people
- Number of esophageal cancer patients in North America2.2 10,000 people
- Number of esophageal cancer patients in Japan2 10,000 people
- Number of esophageal cancer patients in the United Kingdom1 10,000 people
| Item | Details |
|---|---|
| Key KPIs | Indicator name Local complete response rate / Value 50 % / Year on year against the same period last year Not disclosed, Indicator name Local response rate / Value 63.9 % / Year on year against the same period last year Not disclosed, Indicator name Number of complete response cases in the U.S. esophageal cancer CRT trial / Value 13/13 / Year on year against the same period last year Not disclosed, Indicator name 1-year survival rate in the U.S. esophageal cancer CRT trial / Value 60 % / Year on year against the same period last year Not disclosed, Indicator name Cases without local recurrence / Value 12/13 / Year on year against the same period last year Not disclosed, Indicator name Number of patients starting treatment in the U.S. Phase 2 gastric cancer trial / Value 12/13 / Year on year against the same period last year Not disclosed |
| Market Size / Share | Item Asia's share of global esophageal cancer patients / Value 70 %, Item Number of esophageal cancer patients in Asia, including Japan / Value 39 10,000 people, Item Number of esophageal cancer patients in China / Value 20 10,000 people, Item Number of esophageal cancer patients in the EU and the United Kingdom / Value 5.4 10,000 people, Item Number of esophageal cancer patients in North America / Value 2.2 10,000 people, Item Number of esophageal cancer patients in Japan / Value 2 10,000 people, Item Number of esophageal cancer patients in the United Kingdom / Value 1 10,000 people |
| New initiatives | Preparation for Telomelysin's manufacturing and marketing approval, NHI drug price listing, and launch, Additional-indication trials outside esophageal cancer, Overseas expansion prioritizing Asia and the United Kingdom, and sales partnerships, Establishment of an in-house sales organization in Japan, Bridging working capital from manufacturing through cash collection using bank borrowings, Significant expansion of the workforce with drug discovery development experience and biomanufacturing skills, Preparation to launch an investigator-initiated clinical trial of OBP-702 for pancreatic cancer |
Items this document does not state (28)
Document typeFiscal Period CoveredNet SalesOperating profitOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company indicated a policy of expanding value and revenue opportunities by establishing a brand in the esophageal cancer field, adding indications, and expanding overseas, starting with Telomelysin's approval and launch. It cited the concentration of esophageal cancer patients in Asia, the ability to use Japanese clinical data, and the possibility of filing applications in the United Kingdom using overseas data as reasons for overseas expansion.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.